Haardt brings decades of digital healthcare
experience to build on Eyenuk's global mission of using AI to
detect and prevent blinding eye diseases
LOS
ANGELES, July 18, 2024 /PRNewswire/ -- Eyenuk, a
global artificial intelligence (AI) digital health company and
leader in real-world applications for AI Eye Screening™ and AI
Predictive Biomarkers™, today announced the appointment of
Bryan Haardt as Chief Executive
Officer. With over 25 years of experience founding and leading
healthcare technology enterprises, Haardt takes the helm at Eyenuk
to guide the Company into a new era.
Bryan Haardt
brings over 25 years of experience founding and leading healthcare
technology enterprises.
Paul Praino, previously Eyenuk's
interim CEO, will continue to serve the Company as Chief Commercial
Officer, his role before taking the interim job.
"I'm deeply honored to join Eyenuk and lead the next phase of
our journey to ensure timely diagnosis of vision-threatening and
life-threatening diseases through the Company's solutions," said
Haardt.
Eyenuk's flagship EyeArt® AI eye screening system is the only
autonomous AI solution to be both FDA-cleared in the U.S. for the
detection of diabetic retinopathy (DR) and CE-marked under the EU
MDR for the detection of DR as well as age-related macular
degeneration and glaucomatous optic nerve damage. Providers across
the U.S. and in 26 other countries have used the EyeArt AI system
to screen over 300,000 patients since 2020.
"On behalf of the Board of Directors, we are excited to welcome
Bryan and believe he is the ideal operating leader to shepherd
Eyenuk into its next stage of commercial growth," said Eyenuk
Executive Chairman Rob Binney.
"Bryan's track record of execution and value creation as an
entrepreneur, product innovator and executive leader will be
invaluable as Eyenuk extends its leadership in autonomous screening
of blinding eye diseases, as well as in the development of new
lines of AI screening for additional diseases. The Board of
Directors wishes to thank Paul for his leadership during our recent
transition, and for his efforts to ensure a seamless transition of
Bryan into the role of CEO."
Haardt most recently served as leader of digital therapeutics
and prescription digital therapeutics for Boehringer Ingelheim, the
global pharmaceutical company. Prior to that, he was General
Manager of Boehringer Ingelheim's Pawru, whose innovative digital
platform connects veterinary professionals and pet owners. Haardt
is also the co-founder and former CEO of Decisio Health Inc., a
healthcare IT company that delivers actionable information through
digital solutions to improve healthcare. Those solutions include
the first web-native, real-time clinical surveillance and data
visualization platform to receive FDA 510(k) class II
clearance.
Prior to forming Decisio, Haardt served as the Chief Operating
Officer for Prognosis Health Information Systems, Inc. In addition,
Haardt was the founder and CTO of Cgate Health, Inc., a DFJ Mercury
portfolio company. Haardt began his career as the founder and
President of 10X Labs, Inc. 10X Labs was the first company to be
admitted into the Intel Incubation Program and counted Compaq
amongst its investors.
Haardt graduated Cum Laude from the University of Houston where he was a distinguished
student and member of the Honors College studying artificial
intelligence and neural networks.
About Eyenuk, Inc.
Eyenuk, Inc. is a global artificial intelligence (AI) digital
health company and the leader in real-world AI Eye Screening™ for
autonomous disease detection and AI Predictive Biomarkers™ for risk
assessment and disease surveillance. Eyenuk is on a mission to
screen every eye in the world to ensure timely diagnosis of life-
and vision-threatening diseases, including diabetic retinopathy
(DR), glaucoma, age-related macular degeneration (AMD), stroke
risk, cardiovascular risk, and Alzheimer's disease.
Eyenuk's flagship product, the EyeArt AI system, provides
fully autonomous screening for vision- threatening eye disease
based on international clinical standards and immediate reporting
in a single office visit during a patient's regular exam. The
EyeArt AI system has CE marking as a class IIb medical
device in the European Union under the Medical Devices Regulation
2017/745 ("MDR") for the detection of DR, AMD, and glaucomatous
optic nerve damage. The system has also been validated by the U.K.
National Health Service and has both U.S. Food and Drug
Administration clearance and a Health Canada license for autonomous
detection of DR.
Find Eyenuk
online on its website, Twitter, Facebook, and LinkedIn.
Media Contact:
Todd Stein
Todd Stein Communications
todd@toddsteincommunications.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/eyenuk-appoints-bryan-haardt-as-chief-executive-officer-302199943.html
SOURCE Eyenuk, Inc.